Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.77
-0.02 (-2.99%)
Market open: Aug 12, 2026, 3:19 PM EDT
0.78
-0.01 (-1.05%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
| Name | Position |
|---|---|
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary |
| Mr. David Sesin Ph.D. | Chief Manufacturing Officer |
| Mr. Ian H. Wendt M.B.A. | Chief Business Officer |
| Mr. Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & General Counsel |
| Mr. Peter Hodge | Senior Director of Investor Relations, Business Development & Special Events |
| Ms. Carol R. Lizak M.B.A. | CFO & Treasurer |
| Ms. Lisa A. Conte | Founder, CEO, President & Director |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | POS AM | d47881dposam.htm |
| 2026-08-03 | DEF 14A | d165765ddef14a.htm |
| 2026-07-24 | S-1/A | d47881ds1a.htm |
| 2026-07-24 | PRE 14A | d165765dpre14a.htm |
| 2026-07-16 | S-1 | d117884ds1.htm |
| 2026-07-14 | 8-K | d144017d8k.htm |
| 2026-07-01 | 8-K | d145900d8k.htm |
| 2026-06-25 | 8-K | d110630d8k.htm |
| 2026-06-22 | 8-K/A | d121487d8ka.htm |
| 2026-06-18 | 8-K | d111863d8k.htm |